Medtech & Pharma Platform Association

Tweet this page
Registration as it was on 12 Jan 2024
How to read and use this data card.
Download this datacard


Lobbying Costs

100,000€ - 199,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

0.75 Fte (2)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    Medtech & Pharma Platform Association   (MPP)

    EU Transparency Register

    234427831877-10 First registered on 25 Jun 2018

    Goals / Remit

    The Medtech & Pharma Platform Association (MPP) is a European cross-sectoral not-for-profit industry Association focusing on combined products, i.e. products that combine drugs, devices, diagnostics and/or digital elements to fulfill a medical purpose. Members are medtech, diagnostic, pharma and tech companies as well as organizations dedicated to enhancing synergies between the sectors. Current and future innovative healthcare solutions increasingly rely on combined products, integrating various combinations of pharma, medtech and digital technologies. MPP offers expertise and seeks dialogue with relevant stakeholders to collaborate on a proportionate regulatory framework for combined products, with a view to facilitate patient access to innovation, foster European competitiveness and enhance the safety of health data.

    Main EU files targeted

    The Medtech & Pharma Platform Association was founded in 2017 and started its activities in 2018.

    The Medtech & Pharma Platform monitors EU legislative, policy and regulatory developments relating to combined products.

    Specifically, the Medtech & Pharma Platform follows:
    • Medical Devices Regulation EU 2017/745 & In vitro Diagnostics Regulation EU 2017/746
    and their implementing and delegated acts as well as any related guidance document
    • Medicinal Products Directive EU 2001/83
    • EU Pharmaceutical Strategy
    • Revision of the EU basic pharmaceutical legislation
    • Advanced Therapy Medicinal Product Regulation EU 1394/2007
    • Regulation on Health Technology Assessment EU 2021/2282
    • EMA Quality Innovation Group
    • Regulation on standards of quality and safety for substances of human origin
    • Regulation on the classification, labelling and packaging of chemicals
    • General Data Protection Regulation EU 2016/679
    • Clinical Trials Regulation EU 536/2014
    • Accelerating Clinical Trials in the EU (ACT EU)
    • Implementation of the Union list of critical medicines
    • Critical Raw Materials Act
    • Policy initiatives, projects, events and publications from DG SANTE, DG GROW, DG CONNECT, DG RESEARCH & INNOVATION
    • European Health and Digital Executive Agency (HaDEA)
    • Health emergency preparedness and response authority (HERA)
    • European Industrial strategy
    • European Digital Strategy and Artificial Intelligence
    • Horizon Europe
    • European Health Data Space
    • Data Governance Act and Data Act
    • Proposal for Regulation on Artificial Intelligence
    • EU AI Observatory
    • EU Beating Cancer Plan
    • European Health Union
    • Intellectual property action plan
    • Regulation of Ethylene Oxide
    • Regulation of Per- and polyfluoroalkyl substances (PFAS)
    • EMA draft reflection paper on AI and ML
    • EMA “COMBINE” Project
    • Institutional agreement Switzerland-EU


    Head Office
    Medtech & Pharma Platform Association c/o SFL Regulatory Affairs & Scientific Communication GmbH Aeschenvorstadt 52
    Basel 4051
    EU Office
    Medtech & Pharma Platform Association c/o SFL Regulatory Affairs & Scientific Communication GmbH Aeschenvorstadt 52
    Basel 4051


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    No lobbyists with EP accreditations

    Complementary Information

    Within the cluster of 25% working time, two people work 12.5% making a joint total of 25%. In total, 3 people are involved.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Trade and business associations

  • Networking



    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    100,000€ - 199,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    None declared

    Intermediaries for current year

    None declared

    Closed year Costs

    100,000€ - 199,999€

    Other financial info

    MPP is funded by membership contributions.

  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)


    Communication activities

    Stakeholder engagement, projects:
    The MPP engages with relevant stakeholders on a European level, offers expertise and seeks dialogue to collaborate on a proportionate regulatory framework for combined products.

    MPP has three active working groups:
    • Working Group on Combined Products, focusing on co-packaged and non co-packaged drug-device-combinations and single integral combination products,
    • Working Group on Connected Combined Products, focusing on connected combined products including drugs, medical devices, in-vitro diagnostics, digital applications,
    • Working Group on in vitro diagnostics and companion diagnostics.

    • Position paper on the Interface between the EU MDR, IVDR and CTR: Challenges in conducting clinical trials involving medicinal products with medical devices or IVDs
    • Paper on regulatory pathways for connected combined products, examining the challenges associated with regulatory pathways in the EU for a subset of connected combined products consisting of a medicinal product used with a delivery device with wireless connectivity to a standalone software, September 2023
    • T.C. Kühler and al., Development and Regulation of Connected Combined Products: Reflections From the Medtech & Pharma Platform Association, Clinical Therapeutics, Volume 44, ISSUE 5, P768-782, 1 May 2022
    • MPP Best Practice Guide for clinical trials with integral Drug-Device Combination Products including change control and usability studies, December 2020
    • Position paper on the legislative framework for Connected Combined Products, October 2020
    • Reflection paper on regulatory uncertainties for co-packaged and cross-labelled drug-device combinations under the new Medical Device Regulation, December 2019
    • White Paper on EU regulatory and policy framework for combined products, October 2018

    • MPP annual conference: The annual MPP conference is the leading event in the sector of products and solutions that combine pharma, medtech, diagnostic and digital components. The event is dedicated to enhancing synergies between these sectors. The conference provides a forum to exchange knowledge, identify new challenges and opportunities, initiate collaborations and propose improvements to regulatory frameworks and policy, toward the goal of improving patient access to innovative combined products

    • MPP webinars: The MPP Association offers webinars providing comprehensive and up-to-date insights on the latest regulatory and legislative developments related to combined products, medicinal products, medical devices, and in-vitro diagnostics.

    Other activities

    MPP is acknowledged as Industry stakeholder for interaction with the European Medicines Agency (EMA)

  • Meetings


    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: All information below comes from European Commission web pages.

Download this datacard